|Mr. Lawrence A. Kenyon||Pres, CEO, CFO, Company Sec., Treasurer & Director||389.94k||N/A||1966|
|Mr. Terry Dagnon||Chief Operating Officer||N/A||N/A||1962|
|Rick Gregory||Director of Marketing & Communications||N/A||N/A||N/A|
|Mr. Jeffrey Evanson||Chief Commercial Officer||N/A||N/A||1969|
|Dr. Balu N. Balasubramanian Ph.D.||Advisor||N/A||N/A||N/A|
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibody for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in first clinical trial for the treatment of wet age related macular degeneration and other retina diseases. The company has collaboration and license agreements with MTTR, LLC; IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in December 2018. The company was founded in 2010 and is headquartered in Cranbury, New Jersey.
Outlook Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.